Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study (Q43657215)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Igor N. Bondarenko

11

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

author name string

Tim Eisen

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Yaroslav Shparyk

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Nicholas Macleod

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Robert Jones

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Gudrun Wallenstein

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Graham Temple

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Yasser Khder

7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Claudia Dallinger

8

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Matus Studeny

9

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Arsene-Bienvenu Loembe

10

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

publication date

27 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

1283-1293

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Modes of resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Timing of new black box warnings and withdrawals for prescription medications

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Cardiac toxicity: old and new issues in anti-cancer drugs.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Assessing proarrhythmic potential of drugs when optimal studies are infeasible.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9962-7

21 January 2018

An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23625328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New precompetitive paradigms: focus on cardiac safety

1 reference

https://pubmed.ncbi.nlm.nih.gov/23625328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Baseline heart rate-corrected QT and eligibility for clinical trials in oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/23625328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23625328

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-013-9962-7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43657215&oldid=2206187560"